Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9704 |
High Similarity |
NPD6190 |
Approved |
0.8489 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.8194 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.8117 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7956 |
Intermediate Similarity |
NPD9269 |
Phase 2 |
0.7866 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7853 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7831 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7771 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7721 |
Intermediate Similarity |
NPD9545 |
Approved |
0.7707 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7697 |
Intermediate Similarity |
NPD7685 |
Pre-registration |
0.7669 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7667 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7664 |
Intermediate Similarity |
NPD9268 |
Approved |
0.7662 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7654 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7654 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7654 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7643 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7595 |
Intermediate Similarity |
NPD5402 |
Approved |
0.758 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7569 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.7552 |
Intermediate Similarity |
NPD9494 |
Approved |
0.755 |
Intermediate Similarity |
NPD8166 |
Discontinued |
0.7534 |
Intermediate Similarity |
NPD943 |
Approved |
0.7532 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7532 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.753 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7518 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7516 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.7485 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7466 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7453 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7452 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.745 |
Intermediate Similarity |
NPD651 |
Clinical (unspecified phase) |
0.7421 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.741 |
Intermediate Similarity |
NPD7054 |
Approved |
0.741 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7403 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7403 |
Intermediate Similarity |
NPD6799 |
Approved |
0.7397 |
Intermediate Similarity |
NPD3764 |
Approved |
0.7389 |
Intermediate Similarity |
NPD3455 |
Phase 2 |
0.7365 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7365 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7358 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.7358 |
Intermediate Similarity |
NPD37 |
Approved |
0.7349 |
Intermediate Similarity |
NPD3751 |
Discontinued |
0.7337 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7329 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7329 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7329 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7317 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7312 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.7297 |
Intermediate Similarity |
NPD1613 |
Approved |
0.7297 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.7284 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7279 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7267 |
Intermediate Similarity |
NPD8150 |
Discontinued |
0.7261 |
Intermediate Similarity |
NPD5403 |
Approved |
0.7261 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7246 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7212 |
Intermediate Similarity |
NPD3787 |
Discontinued |
0.72 |
Intermediate Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.7188 |
Intermediate Similarity |
NPD6385 |
Approved |
0.7188 |
Intermediate Similarity |
NPD6386 |
Approved |
0.7186 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7181 |
Intermediate Similarity |
NPD7966 |
Clinical (unspecified phase) |
0.7171 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.7171 |
Intermediate Similarity |
NPD9570 |
Approved |
0.7169 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7168 |
Intermediate Similarity |
NPD8434 |
Phase 2 |
0.7164 |
Intermediate Similarity |
NPD9265 |
Clinical (unspecified phase) |
0.7162 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.716 |
Intermediate Similarity |
NPD5353 |
Approved |
0.7152 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7134 |
Intermediate Similarity |
NPD5401 |
Approved |
0.7133 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7133 |
Intermediate Similarity |
NPD447 |
Suspended |
0.7125 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.7114 |
Intermediate Similarity |
NPD4062 |
Phase 3 |
0.7086 |
Intermediate Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.7078 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.7067 |
Intermediate Similarity |
NPD825 |
Approved |
0.7067 |
Intermediate Similarity |
NPD826 |
Approved |
0.705 |
Intermediate Similarity |
NPD2629 |
Approved |
0.7048 |
Intermediate Similarity |
NPD8127 |
Discontinued |
0.7032 |
Intermediate Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.7027 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.7025 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7021 |
Intermediate Similarity |
NPD5536 |
Phase 2 |
0.7 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.6994 |
Remote Similarity |
NPD7819 |
Suspended |
0.6993 |
Remote Similarity |
NPD1510 |
Phase 2 |
0.6993 |
Remote Similarity |
NPD7033 |
Discontinued |
0.6988 |
Remote Similarity |
NPD5494 |
Approved |
0.6987 |
Remote Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.6987 |
Remote Similarity |
NPD4110 |
Phase 3 |
0.698 |
Remote Similarity |
NPD7095 |
Approved |
0.6968 |
Remote Similarity |
NPD1549 |
Phase 2 |
0.6966 |
Remote Similarity |
NPD1608 |
Approved |
0.6964 |
Remote Similarity |
NPD5242 |
Approved |
0.6959 |
Remote Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.6954 |
Remote Similarity |
NPD4060 |
Phase 1 |
0.6948 |
Remote Similarity |
NPD1551 |
Phase 2 |
0.6934 |
Remote Similarity |
NPD3021 |
Approved |
0.6934 |
Remote Similarity |
NPD3022 |
Approved |
0.6918 |
Remote Similarity |
NPD2533 |
Approved |
0.6918 |
Remote Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.6918 |
Remote Similarity |
NPD3146 |
Approved |
0.6918 |
Remote Similarity |
NPD3688 |
Clinical (unspecified phase) |
0.6918 |
Remote Similarity |
NPD2532 |
Approved |
0.6918 |
Remote Similarity |
NPD2534 |
Approved |
0.6908 |
Remote Similarity |
NPD4340 |
Discontinued |
0.6908 |
Remote Similarity |
NPD555 |
Phase 2 |
0.6903 |
Remote Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.6903 |
Remote Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.6897 |
Remote Similarity |
NPD1535 |
Discovery |
0.6879 |
Remote Similarity |
NPD6559 |
Discontinued |
0.6879 |
Remote Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.6879 |
Remote Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.6879 |
Remote Similarity |
NPD3750 |
Approved |
0.6871 |
Remote Similarity |
NPD7411 |
Suspended |
0.6863 |
Remote Similarity |
NPD6653 |
Approved |
0.6855 |
Remote Similarity |
NPD4357 |
Discontinued |
0.6849 |
Remote Similarity |
NPD1481 |
Phase 2 |
0.6842 |
Remote Similarity |
NPD1240 |
Approved |
0.6835 |
Remote Similarity |
NPD228 |
Approved |
0.6835 |
Remote Similarity |
NPD3887 |
Approved |
0.6835 |
Remote Similarity |
NPD2354 |
Approved |
0.6833 |
Remote Similarity |
NPD6535 |
Approved |
0.6833 |
Remote Similarity |
NPD6534 |
Approved |
0.6831 |
Remote Similarity |
NPD9493 |
Approved |
0.6826 |
Remote Similarity |
NPD919 |
Approved |
0.6813 |
Remote Similarity |
NPD7422 |
Clinical (unspecified phase) |
0.6812 |
Remote Similarity |
NPD2067 |
Discontinued |
0.6811 |
Remote Similarity |
NPD7435 |
Discontinued |
0.6788 |
Remote Similarity |
NPD8455 |
Phase 2 |
0.6788 |
Remote Similarity |
NPD1358 |
Approved |
0.6782 |
Remote Similarity |
NPD7039 |
Approved |
0.6782 |
Remote Similarity |
NPD7038 |
Approved |
0.6782 |
Remote Similarity |
NPD7240 |
Approved |
0.6779 |
Remote Similarity |
NPD257 |
Approved |
0.6779 |
Remote Similarity |
NPD6007 |
Clinical (unspecified phase) |
0.6779 |
Remote Similarity |
NPD258 |
Approved |
0.6776 |
Remote Similarity |
NPD259 |
Phase 1 |
0.6776 |
Remote Similarity |
NPD6663 |
Approved |
0.677 |
Remote Similarity |
NPD7314 |
Clinical (unspecified phase) |
0.6765 |
Remote Similarity |
NPD3926 |
Phase 2 |
0.6759 |
Remote Similarity |
NPD1778 |
Approved |
0.6759 |
Remote Similarity |
NPD17 |
Approved |
0.6757 |
Remote Similarity |
NPD3225 |
Approved |
0.6753 |
Remote Similarity |
NPD1607 |
Approved |
0.6752 |
Remote Similarity |
NPD5958 |
Discontinued |
0.6752 |
Remote Similarity |
NPD4534 |
Discontinued |
0.6746 |
Remote Similarity |
NPD1247 |
Approved |
0.6739 |
Remote Similarity |
NPD6779 |
Approved |
0.6739 |
Remote Similarity |
NPD6776 |
Approved |
0.6739 |
Remote Similarity |
NPD6780 |
Approved |
0.6739 |
Remote Similarity |
NPD6778 |
Approved |
0.6739 |
Remote Similarity |
NPD6781 |
Approved |
0.6739 |
Remote Similarity |
NPD6782 |
Approved |
0.6739 |
Remote Similarity |
NPD6777 |
Approved |
0.6736 |
Remote Similarity |
NPD1894 |
Discontinued |
0.6733 |
Remote Similarity |
NPD5736 |
Approved |
0.6733 |
Remote Similarity |
NPD9569 |
Approved |
0.6731 |
Remote Similarity |
NPD2438 |
Suspended |
0.6731 |
Remote Similarity |
NPD2796 |
Approved |
0.6721 |
Remote Similarity |
NPD7700 |
Phase 2 |
0.6721 |
Remote Similarity |
NPD7699 |
Phase 2 |
0.6712 |
Remote Similarity |
NPD3496 |
Discontinued |
0.6711 |
Remote Similarity |
NPD1203 |
Approved |
0.671 |
Remote Similarity |
NPD7097 |
Phase 1 |
0.6709 |
Remote Similarity |
NPD1652 |
Phase 2 |
0.6708 |
Remote Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.6705 |
Remote Similarity |
NPD8313 |
Approved |
0.6705 |
Remote Similarity |
NPD8312 |
Approved |
0.6692 |
Remote Similarity |
NPD9495 |
Approved |
0.669 |
Remote Similarity |
NPD690 |
Clinical (unspecified phase) |
0.6689 |
Remote Similarity |
NPD2983 |
Phase 2 |
0.6689 |
Remote Similarity |
NPD2982 |
Phase 2 |
0.6688 |
Remote Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.6688 |
Remote Similarity |
NPD5763 |
Approved |
0.6688 |
Remote Similarity |
NPD5762 |
Approved |
0.6687 |
Remote Similarity |
NPD3687 |
Approved |
0.6687 |
Remote Similarity |
NPD3686 |
Approved |
0.6686 |
Remote Similarity |
NPD8368 |
Discontinued |
0.6684 |
Remote Similarity |
NPD8320 |
Phase 1 |
0.6684 |
Remote Similarity |
NPD8319 |
Approved |
0.6667 |
Remote Similarity |
NPD3749 |
Approved |
0.6667 |
Remote Similarity |
NPD5647 |
Approved |
0.6667 |
Remote Similarity |
NPD3400 |
Discontinued |
0.6667 |
Remote Similarity |
NPD422 |
Phase 1 |
0.6667 |
Remote Similarity |
NPD1091 |
Approved |
0.6647 |
Remote Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.6646 |
Remote Similarity |
NPD2424 |
Discontinued |
0.6646 |
Remote Similarity |
NPD3226 |
Approved |
0.6644 |
Remote Similarity |
NPD9381 |
Approved |
0.6644
|
Remote Similarity |
NPD9384 |
Approved |